OncoMethylome Sciences Signs Agreement for GlaxoSmithKline Biologicals Immunotherapy Development Program

24-Sep-2010 - Belgium

OncoMethylome Sciences announced that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

OncoMethylome's biomarker is stable, highly accurate, and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.

"We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D., Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methylation specific PCR platform in the rapidly emerging field of companion diagnostics and personalized medicine."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures